Prognostic role of ECOG performance status in patients with urothelial carcinoma of the upper urinary tract: An international study

BJU International

Volumn 109, Issue 8, 2012, Pages 1155-1161

  Martinez Salamanca, Juan Ignacio ^a   Shariat, Shahrokh F ^b   Rodriguez, Joaquin Carballido ^a   Chromecki, Thomas F ^b   Ficarra, Vincenzo ^c   Fritsche, Hans Martin ^d   Kassouf, Wassim ^e   Matsumoto, Kazumasa ^f   Cabello, Lucia Osorio ^a   Seitz, Christian ^g   Tritschler, Stefan ^h   Walton, Thomas J ⁱ   Zattoni, Filiberto ^c   Novara, Giacomo ^c  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^f KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g CENTRAL HOSPITAL OF BOLZANO   (Italy)

^h LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁱ DERBY CITY GENERAL HOSPITAL   (United Kingdom)

Author keywords

Cancer specific mortality; ECOG; Nephroureterectomy; Performance status; Prognosis; Recurrence free survival; Urinary tract cancer; Urothelial carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; ELECTROCORTICOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROURETERECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CARCINOMA;

AGED; ASIA; CARCINOMA, TRANSITIONAL CELL; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NORTH AMERICA; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; UROLOGIC NEOPLASMS; UROLOGIC SURGICAL PROCEDURES;

EID: 84859452058     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10479.x     Document Type: Article

References (24)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300
2. Margulis V, Shariat SF, Matin SF et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009; 115: 1224-33
3. Kang CH, Yu TJ, Hsieh HH et al. The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer 2003; 98: 1620-6 (Pubitemid 37238617)
4. Langner C, Hutterer G, Chromecki T, Leibl S, Rehak P, Zigeuner R. Tumor necrosis as prognostic indicator in transitional cell carcinoma of the upper urinary tract. J Urol 2006; 176: 910-3; discussion 913-4
5. Lughezzani G, Jeldres C, Isbarn H et al. Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population based study of 2299 patients. Eur J Cancer 2009; 45: 3291-7
6. Novara G, De Marco V, Gottardo F et al. Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers. Cancer 2007; 110: 1715-22 (Pubitemid 47557295)
7. Rabbani F, Perrotti M, Russo P, Herr HW. Upper-tract tumors after an initial diagnosis of bladder cancer: argument for long-term surveillance. J Clin Oncol 2001; 19: 94-100 (Pubitemid 32063484)
8. Roscigno M, Shariat SF, Margulis V et al. Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol 2009; 181: 2482-9
9. Roscigno M, Shariat SF, Margulis V et al. The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed? Eur Urol 2009; 56: 512-8
10. Zigeuner R, Pummer K. Urothelial carcinoma of the upper urinary tract: surgical approach and prognostic factors. Eur Urol 2008; 53: 720-31
11. Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 1998; 52: 594-601 (Pubitemid 28440164)
12. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55 (Pubitemid 13149996)
13. Greene FL, Page DL, Fleming ID et al. American Joint Committee on Cancer (AJCC) Staging Manual, 6th edn. Philadelphia: Springer, 2002
14. Mostofi FK, Sobin LH, Torloni H. Histological Typing of Urinary Bladder Tumors. Geneva, Switzerland: WHO, 1973
15. Ecke TH, Gerullis H, Bartel P, Koch S, Ruttloff J. Gemcitabine, paclitaxel, and cisplatin as combined adjuvant approach in transitional cell carcinoma of the urothelium. Minerva Urol Nefrol 2009; 61: 249-56
16. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068-77
17. Capitanio U, Shariat SF, Isbarn H et al. Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur Urol 2009; 56: 1-9
18. Walton TJ, Sherwood BT, Parkinson RJ et al. Comparative outcomes following endoscopic ureteral detachment and formal bladder cuff excision in open nephroureterectomy for upper urinary tract transitional cell carcinoma. J Urol 2009; 181: 532-9
19. Novara G, Matsumoto K, Kassouf W et al. Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur Urol 2010; 57: 1064-71
20. Remzi M, Haitel A, Margulis V et al. Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int 2009; 103: 307-11
21. Fritsche HM, Novara G, Burger M et al. Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma. Urol Oncol 2010; Oct 6 [epub ahead of print]
22. Wheat JC, Weizer AZ, Wolf JS Jr et al. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. Urol Oncol 2010; May 5 [epub ahead of print]
23. Seitz C, Gupta A, Shariat SF et al. Association of tumor necrosis with pathological features and clinical outcome in 754 patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma: an international validation study. J Urol 2010; 184: 1895-900
24. Zigeuner R, Shariat SF, Margulis V et al. Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol 2010; 57: 575-81